Equities analysts predict that Bristol-Myers Squibb Company (NYSE:BMY) will report $0.67 earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Six analysts have issued estimates for Bristol-Myers Squibb’s earnings, with the highest EPS estimate coming in at $0.70 and the lowest estimate coming in at $0.63. Bristol-Myers Squibb posted earnings of $0.63 per share during the same quarter last year, which would indicate a positive year over year growth rate of 6.3%. The business is scheduled to announce its next earnings report on Thursday, January 25th.
According to Zacks, analysts expect that Bristol-Myers Squibb will report full-year earnings of $2.99 per share for the current financial year, with EPS estimates ranging from $2.96 to $3.03. For the next year, analysts expect that the firm will report earnings of $3.19 per share, with EPS estimates ranging from $3.03 to $3.54. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that follow Bristol-Myers Squibb.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.77 by ($0.02). The business had revenue of $5.25 billion during the quarter, compared to analyst estimates of $5.20 billion. Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The firm’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.77 EPS.
A number of analysts have commented on BMY shares. Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and set a $63.00 price target on shares of Bristol-Myers Squibb in a research report on Wednesday, August 9th. Vetr cut Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $63.81 price target for the company. in a research report on Wednesday, August 9th. Jefferies Group LLC reaffirmed a “buy” rating and set a $66.00 price target (up previously from $63.00) on shares of Bristol-Myers Squibb in a research report on Thursday, August 24th. UBS AG reaffirmed a “buy” rating and set a $72.00 price target (up previously from $62.00) on shares of Bristol-Myers Squibb in a research report on Friday, October 6th. Finally, Citigroup Inc. lifted their price target on Bristol-Myers Squibb to $72.00 and gave the stock a “buy” rating in a research report on Wednesday, October 18th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and eleven have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $64.93.
In other news, SVP Joseph C. Caldarella sold 9,340 shares of the business’s stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total transaction of $560,400.00. Following the transaction, the senior vice president now directly owns 46,297 shares in the company, valued at approximately $2,777,820. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 0.23% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in BMY. Renaissance Technologies LLC lifted its holdings in Bristol-Myers Squibb by 108.5% in the second quarter. Renaissance Technologies LLC now owns 13,488,200 shares of the biopharmaceutical company’s stock valued at $751,563,000 after acquiring an additional 7,020,200 shares during the last quarter. Franklin Resources Inc. raised its position in Bristol-Myers Squibb by 185.2% in the second quarter. Franklin Resources Inc. now owns 6,098,935 shares of the biopharmaceutical company’s stock valued at $339,830,000 after purchasing an additional 3,960,191 shares during the period. Jennison Associates LLC raised its position in Bristol-Myers Squibb by 16.2% in the third quarter. Jennison Associates LLC now owns 26,854,242 shares of the biopharmaceutical company’s stock valued at $1,711,689,000 after purchasing an additional 3,735,453 shares during the period. Janus Henderson Group PLC raised its position in Bristol-Myers Squibb by 2,990.5% in the second quarter. Janus Henderson Group PLC now owns 3,634,128 shares of the biopharmaceutical company’s stock valued at $202,494,000 after purchasing an additional 3,516,536 shares during the period. Finally, Arrowstreet Capital Limited Partnership raised its position in Bristol-Myers Squibb by 42,071.5% in the second quarter. Arrowstreet Capital Limited Partnership now owns 3,331,549 shares of the biopharmaceutical company’s stock valued at $185,634,000 after purchasing an additional 3,323,649 shares during the period. Hedge funds and other institutional investors own 69.51% of the company’s stock.
Bristol-Myers Squibb (BMY) traded up $0.26 during trading on Friday, hitting $61.25. The stock had a trading volume of 3,825,908 shares, compared to its average volume of 8,719,474. Bristol-Myers Squibb has a 52-week low of $46.01 and a 52-week high of $66.10. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.59 and a quick ratio of 1.46. The firm has a market cap of $100,250.00, a PE ratio of 20.56, a price-to-earnings-growth ratio of 2.40 and a beta of 1.18.
The business also recently announced a quarterly dividend, which was paid on Wednesday, November 1st. Stockholders of record on Friday, October 6th were issued a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a dividend yield of 2.55%. The ex-dividend date was Thursday, October 5th. Bristol-Myers Squibb’s dividend payout ratio is currently 61.42%.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.